iBio
Biotechnology, Manufacturing · 16 employees
iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs.
Funding history
- Venture - Series Unknown — $26.0M — Jan 2026
- Venture - Series Unknown — $11.1M — May 2025
- Venture - Series Unknown — $15.1M — Apr 2024
- Post-IPO Equity — $15.0M — Mar 2024
Recent signals
- Jan 22, 2026: Raised $26.0M in Venture - Series Unknown
- Nov 20, 2025: SEC 8-K (5.02): On November 20, 2025, iBio, Inc. conducted its Annual Meeting of Stockholders where stockholders voted on four proposals including the election of two Class II directors to the Board, each to serve a three-year term expiring at the 2028 Annual Meeting. A total of 10,566,364 shares were represented, fulfilling the quorum requirement. The nominees successfully elected will contribute to the strategic direction of the company for the next three years, aligning with the company's governance and future planning initiatives.
- May 07, 2025: Raised $11.1M in Venture - Series Unknown
- Jan 13, 2025: iBio Announces New Investments from Board Members and Officers
- Jan 07, 2025: iBio Collaborates with AstralBio to Develop Antibody Targeting Activin E
- Jan 02, 2025: Launched iBio, Inc. expands its cardiometabolic and obesity treatment program with the anti-myostatin antibody IBIO-600, licensed from AstralBio.
- Aug 12, 2024: iBio, Inc. Appoints Kristi Sarno as Senior Vice President, Business Development
- Apr 04, 2024: Raised $15.1M in Venture - Series Unknown
See plans & pricing → Track iBio’s funding, hiring, and signals — with verified contacts — on Fundz.